Psoriasis

LOUISVILLE, Ky. — Persistent, chronic inflammation seen in moderate to severe psoriasis is associated with plaque destabilization and rupture that drives MI, and biologic treatment can reduce CV risk, according to a speaker.

A novel biosimilar for adalimumab was associated with bio-equivalent pharmacokinetics and safety as the reference product in patients with moderate to severe plaque psoriasis, according to study findings.

A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.

Compared with a number of other biologics used to treat psoriasis, guselkumab was associated with strong long-term drug survival as a function of both effectiveness and safety, according to study findings.

A new artificial intelligence tool may improve diagnosis speed in patients with psoriatic arthritis, according to a press release summarizing data from the European Academy of Dermatology and Venereology’s Spring Symposium 2022.

Ixekizumab was associated with greater efficacy than etanercept in a cohort of European patients with moderate to severe psoriasis, regardless of reimbursement criteria in the country where the patient was treated, according to a study.

An 8-week course of daily probiotics was associated with improvements in a number of psoriasis disease parameters, including quality of life, according to study findings.

What psoriasis treatment is as effective as adalimumab but achieves better overall improvement in health-related quality of life, as well as improves patient report of pain, lowers markers of systemic inflammation that cause cardiovascular disease, improves levels of HDL (ie, good cholesterol) and requires no laboratory screening?

Psoriasis treatment options have come a long way, but phototherapy, one of the oldest treatments around, is still a mainstay in many dermatologists’ offices offering safe, effective management of plaque psoriasis.

Researchers found that monitoring circulating levels of Siliq correlated with clinical response in patients treated for psoriasis, according to a study published in JAMA Dermatology.